drugset / Trial / NCT03512834
Paclitaxel-Avelumab for Angiosarcoma
NaSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy of Avelumab when given in combination with paclitaxel as a first line treatment for the patients with inoperable angiosarcoma.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2022-11
- Completion
- 2023-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |